Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept for Macular Edema Secondary to BRVO
NCT03108352Phase 3Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Apr 2016
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of conbercept in macular edema, sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Started Apr 2016; status: completed.
02
Drugs
conbercept
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT03108352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108352.